Comprehensive Blood Panel

What is a comprehensive blood panel?

A comprehensive blood panel is a single blood draw that runs dozens of laboratory tests at once, giving a broad picture of how your body is working on the inside. Instead of ordering one test to chase one symptom, a screening panel checks many systems together — blood, metabolism, heart-related fats, organ function, and hormones — in someone who feels perfectly well.

The goal is an early signal. Many common conditions, from prediabetes to an underactive thyroid to early kidney strain, are silent for years but show up as a number quietly drifting outside its reference range long before you would ever feel a symptom.

What it measures

A screening blood panel bundles several standard lab groups into one draw. A comprehensive panel typically includes the groups below — the current package listing shows the exact test list at each tier:

• Complete blood count (CBC) — red cells, white cells, and platelets; flags anemia, infection, and some blood disorders
• Metabolic markers — fasting glucose and HbA1c for diabetes and prediabetes
• Lipid panel — cholesterol and triglycerides for cardiovascular risk
• Liver and kidney function — enzymes and filtration markers that show how those organs are coping
• Thyroid hormones — TSH and related levels that govern metabolism
• Tumor markers — such as AFP, CEA, CA 19-9, CA-125, and PSA

Reading your results, marker by marker

A blood panel is not one test. It is dozens of them printed on the same page, and the reason a report feels overwhelming is that almost none of it is explained. Below are the markers that actually drive decisions — what each one is measuring, and what a number outside its range does and does not mean.

One rule applies to every line on the page: reference ranges are set by the laboratory that ran the sample, and they differ between labs, between analysers, and often between sexes and age groups. That is why your report prints the range next to your value. Read your number against the range beside it, not against a number you found online.

Metabolic — HbA1c

Fasting glucose tells you what your blood sugar was doing during the ten seconds the needle was in your arm. HbA1c is the one that matters, because it is not a snapshot at all. Glucose in your blood sticks to the haemoglobin inside red blood cells, and it keeps sticking across the roughly 120 days those cells circulate. Measuring what fraction of your haemoglobin is sugar-coated therefore reports your average blood sugar over roughly the past two to three months — the recent weeks count most, but the window covers the weekends, the late dinners, and the days you did not know you would be tested. You cannot fast your way to a good HbA1c the night before.

The American Diabetes Association bands are well established and used worldwide:

As with every band table on this site, this is a classification, not a verdict. What the band decides is the next step — repeat and watch, or see someone about it — not who you are.

Liver — ALT and AST

ALT and AST are not toxins or waste products. They are enzymes that live inside liver cells, doing ordinary metabolic work. They only appear in your bloodstream in quantity when liver cells are stressed, inflamed, or dying and leak their contents out. So a raised ALT is not measuring liver damage directly — it is measuring leakage, which is a proxy for irritation somewhere in the liver.

The cutoffs for "high" are genuinely unsettled. They vary by laboratory, by sex, and by the reference population the lab used to define normal, and several groups argue the traditional upper limits are set too high to catch real disease. Your report prints your lab's range next to your value; that is the number your result should be read against.

What most people want to know is what a mildly raised ALT means in someone with no symptoms. In a screening context — no alcohol history worth noting, no medication that stresses the liver, no known hepatitis — the single most common explanation is fatty liver disease: fat accumulating inside liver cells and mildly irritating them. It is common, it is often silent, and in its early stages it is substantially reversible. Blood work can raise the suspicion, but it cannot see fat. The test that actually looks is an abdominal ultrasound, which images the liver directly and can show the characteristic brightness of a fatty one.

A markedly raised ALT, or one climbing across repeat draws, is a different conversation and belongs with a physician rather than a web page.

Cardiovascular — the lipid panel

A lipid panel reports total cholesterol, HDL, triglycerides, and LDL — and LDL is the number that drives decisions. Modern prevention guidelines treat LDL not as a marker that happens to travel alongside heart disease, but as a cause of it: LDL particles physically enter the artery wall and are the raw material plaque is built from. That distinction matters practically, because it is why lowering LDL lowers events rather than merely improving a number on a page. Genetic evidence, large trials across several drug classes, and long-term cohort data converge on the same conclusion — the causal direction has been the mainstream position for years.

But a lipid panel answers only half the question. It tells you the risk factor: how much of the raw material is circulating. It does not tell you whether plaque has actually formed in your arteries. That is the other half, and it is what a calcium score answers — a short CT that measures calcified plaque that is already there. The two are complementary rather than redundant: you can have unremarkable cholesterol and real plaque, or high LDL and a calcium score of zero. Read together they say something neither says alone.

Tumor markers — CEA, CA 125, AFP, PSA

This is the section of the report people read first and understand least, so it is worth being blunt. Tumor markers are substances — mostly proteins — that some tumors release into the blood, and that healthy and irritated tissue also release. CEA is associated with colorectal and some other cancers; CA 125 with ovarian cancer; AFP with liver cancer and certain germ-cell tumors; PSA is made by the prostate. That is what they are. What follows is what they are not.

The specificity problem is concrete, not theoretical. CEA runs higher in smokers — enough that laboratories commonly apply a separate, higher reference range to them — and rises in a range of benign conditions involving inflammation of the gut, liver, or lungs. CA 125 rises with endometriosis, with benign ovarian cysts, with fibroids, and with pelvic inflammation — common conditions, none of them cancer. Which is to say either marker can be raised, unremarkably, in someone who does not have the cancer it is named after. Run these tests across a population of healthy people and most of the raised values you find are not cancer. Each one still buys the person holding it a period of fear and a chain of follow-up tests, some of which carry their own risks.

This is precisely why major guideline bodies do not recommend tumor markers for cancer screening in the general population — and it is worth naming them rather than gesturing at "the guidelines," because they say it separately and specifically. The US Preventive Services Task Force recommends against ovarian cancer screening in women without symptoms, CA 125 included. The National Cancer Institute states that tumor markers generally do not work well as screening tests — they miss cancers, and they flag people who do not have one. ASCO does not recommend CEA as a screening test for colorectal cancer.

Where these markers have real, established value is elsewhere: monitoring someone with a known cancer to see whether treatment is working, and watching for recurrence after treatment. That is a different job, done in a different population, and they are good at it.

PSA is the exception worth stating separately, because its status genuinely differs from the others. Rather than a flat recommendation against, the USPSTF frames PSA screening for men aged 55–69 as an individual decision to be made after discussing the benefits and harms with a clinician, and recommends against it for men aged 70 and over. (That reflects the Task Force's 2018 statement, which is currently under review — worth checking for an update if you are weighing this.)

Which leaves an honest question about why a marker appears on a screening panel at all. The defensible answer is that it belongs there as one weak signal among many, never as a verdict on its own. A marker that is genuinely useful is one read in context — against your history, against the imaging done the same day, and above all against your own previous values. A single CEA means very little. A CEA that has climbed steadily across three annual draws is a question worth asking. That is the only way these numbers earn their place, and anyone presenting them to you as a cancer test is misrepresenting them.

Thyroid — TSH

TSH is the pituitary gland's instruction to the thyroid, and it moves in the opposite direction to what you might expect: a high TSH usually means the pituitary is shouting because the thyroid is under-producing, and a low TSH often means the opposite. It is a sensitive early indicator, which is why it is the standard first-line thyroid test.

What it cannot do is look at the gland. Blood reads function; ultrasound reads structure, and the two come apart constantly — a thyroid full of nodules can produce entirely normal hormone levels, and a structurally unremarkable gland can be badly underactive. If either question is live, a thyroid ultrasound answers the half that blood cannot.

What it can't tell you

Blood chemistry tells you how your body is running — not what a growth looks like. The most misunderstood part of any screening panel is the tumor-marker section, so it is worth being clear about what those numbers can and cannot do.

That is why blood work is strongest paired with pictures. A full-body MRI shows the organs a blood test can only hint at, and if your thyroid hormones look off, a thyroid ultrasound looks straight at the gland itself.

Who should consider it

A comprehensive panel suits adults who want a baseline they can track over time. That includes:

• Anyone wanting a documented starting point to compare against in future years
• People with a family history of diabetes, heart disease, or thyroid problems
• Adults over 40, when several of these numbers naturally start to shift
• Travelers pairing a full check-up with a trip, since blood results come back quickly

It is also the natural companion to any imaging study — the two answer different questions, and a good screening package combines them rather than choosing one.

Before your blood draw

Preparation is simple, but fasting usually matters for accurate results. The standard preparation is below — follow the exact instructions you receive at booking:

1. 1
   Fast beforehand

   Glucose and lipid numbers are only reliable on an empty stomach, so fasting is normally required the night before. Plain water is usually fine — confirm the exact window when you book.
2. 2
   The draw itself

   A nurse fills a few small tubes from a vein in your arm. It takes only a few minutes and there is no scan and no radiation involved.
3. 3
   Eat and carry on

   There is no recovery time — have breakfast right after and continue with the rest of your check-up.

What a comprehensive blood panel costs

Bloodwork is where price transparency breaks down hardest. The same draw can be billed at wildly different rates depending on whether it runs through a hospital, a physician's office, or a direct-to-consumer lab, and the published self-pay spread as of July 2026 has been correspondingly wide — from under a hundred dollars for a basic panel to well into four figures for a broad one with tumor markers and hormones. Insurance generally covers only what a physician can justify as medically necessary, which excludes most screening-scale panels. Verify current figures locally.

At New Dawn Health the panel is priced as one comprehensive draw and is also included in the screening packages; the live pricing further down this page comes from our booking system.

Results & follow-up

You receive a report that lists every value next to its reference range, so you can see at a glance what sits inside normal and what does not. Turnaround and how results are delivered vary by hospital — your coordinator confirms both when you book. Anything out of range comes with a plain recommendation — repeat at a set interval, add a targeted test, or take the result home to your own doctor.

Because it is just numbers on a page, the panel is easy to repeat, which makes it the natural anchor for tracking your health year over year.